-
Covid-19 cases expected to spike in France this summer
The spring booster vaccination campaign is still underway after being extended due to low uptake
-
Video: French police play ‘Titanic’ theme while driving through flooded street in Paris
Fun reaction to storm attracts millions of viewers on social media
-
Ski resort in French Alps to close due to lack of snow and funding cuts
Local officials have announced the closure of the Alpe du Grand Serre station in Isère, halting plans to keep it open year-round
First Covid vaccine approved for EU today
Today's announcement by the European Medicines Agency paves the way for France's vaccination programme to start on time

The Covid-19 vaccine developed by Pfizer and BioNTech has today been authorised by the European Medicines Agency (EMA), one of the last formalities before vaccinations may begin.
It must now be approved by the European Commission, but its president, Ursula von der Leyen, has said this could happen today.
It’s a decisive moment in our efforts to deliver safe & effective vaccines to Europeans!
— Ursula von der Leyen (@vonderleyen) December 21, 2020
The @EMA_News just issued a positive scientific opinion on the #BioNTech / @pfizer vaccine.
Now we will act fast. I expect a @EU_Commission decision by this evening.
Ms von der Leyen said vaccination would now be able to start across the EU from December 27.
This follows approval of the vaccine for use in the UK – which involved an accelerated procedure for temporary permission (allowed by EU law) – and the USA.
The EMA said it was approving the vaccine on certain conditions, notably it should be given only to people aged over 16 and that the American and German firms that developed the vaccine should supply follow-up data on the vaccine for one year.
“This is really a historic scientific achievement," said EMA head Emer Cooke. “It is a significant step forward in our fight against the pandemic.”
The vaccine will be the first to be rolled-out in France and it is hoped that next year another, by Moderna, will receive approval in early January.
It will be offered first to residents in nursing homes and then rolled out progressively to groups deemed less at risk.
Other vaccines are also in the pipeline, from Oxford/AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica and CureVac.